Divergent trajectories of physical, cognitive, and psychosocial aging in schizophrenia

Schizophrenia Bulletin

Volumn 37, Issue 3, 2011, Pages 451-455

  Jeste, Dilip V ^a   Wolkowitz, Owen M ^b   Palmer, Barton W ^a  

^a San Diego   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

biomarkers; geriatric; neuropsychological; psychosis; psychotherapy; quality of life

Indexed keywords

BIOLOGICAL MARKER;

AGING; ARTICLE; BEHAVIOR; BRAIN FUNCTION; COGNITION; COMORBIDITY; COPING BEHAVIOR; DISEASE COURSE; DISEASE SEVERITY; HOSPITALIZATION; HUMAN; MENTAL DISEASE; MORTALITY; NERVE CELL PLASTICITY; PRIORITY JOURNAL; PSYCHOTHERAPY; RELAPSE; REMISSION; SCHIZOPHRENIA; SELF ESTEEM; SOCIAL PSYCHOLOGY; SOCIAL SUPPORT; SURVIVOR; WELLBEING;

ADAPTATION, PSYCHOLOGICAL; AGING; COGNITION; COMORBIDITY; HUMANS; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIAL SUPPORT;

EID: 79955435318     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbr026     Document Type: Article

References (25)

1. Jeste DV, Depp CA, Vahia IV. Successful cognitive and emotional aging. World Psychiatry. 2010;9:78-84.
2. Stone AA, Schwartz JE, Broderick JE, Deaton A. A snapshot of the age distribution of psychological well-being in the United States. Proc Natl Acad Sci U S A. 2010;107: 9985-9990.
3. Kirkpatrick B, Messias E, Harvey PD, Fernandez-Egea E, Bowie CR. Is schizophrenia a syndrome of accelerated aging? Schizophr Bull. 2008;34:1024-1032.
4. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64:1123-1131. (Pubitemid 47529346)
5. Jin H, Folsom D, Sasaki A, et al. Increased Framingham 10- year risk of coronary heart disease in middle-aged and older patients with psychotic symptoms. Schizophr Res. 2011;125: 295-299.
6. Epel ES. Psychological and metabolic stress: a recipe for accelerated cellular aging? Hormones (Athens). 2009;8:7-22.
7. Fan X, Goff DC, Henderson DC. Inflammation and schizophrenia. Expert Rev Neurother. 2007;7:789-796. (Pubitemid 47037719)
8. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry. 2008;63:801-808. (Pubitemid 351410515)
9. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol. 2008;11:851-876.
10. Zhang P, Dilley C, Mattson MP. DNA damage responses in neural cells: focus on the telomere. Neuroscience. 2007;145: 1439-1448. (Pubitemid 46602741)
11. Wolkowitz OM, Mellon SH, Epel ES, Lin J, Dhabhar FS, Su Y. Telomere shortening in chronic major depression. PLoS One. In press.
12. Woodberry KA, Giuliano AJ, Seidman LJ. Premorbid IQ in schizophrenia: a meta-analytic review. Am J Psychiatry. 2008;165:579-587. (Pubitemid 351705334)
13. Palmer BW, Dawes SE, Heaton RK. What do we know about neuropsychological aspects of schizophrenia? Neuropsychol Rev. 2009;19:365-384.
14. Bilder RM, Reiter G, Bates J, et al. Cognitive development in schizophrenia: follow-back from the first episode. J Clin Exp Neuropsychol. 2006;28:270-282. (Pubitemid 43254519)
15. Mesholam-Gately RI, Giuliano AJ, Goff KP, Faraone SV, Siedman LJ. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology. 2009;23:315-336.
16. Heaton RK, Gladsjo JA, Palmer BW, Kuck J, Marcotte TD, Jeste DV. Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry. 2001;58:24-32. (Pubitemid 32057762)
17. Harvey PD, Silverman JM, Mohs RC, et al. Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients. Biol Psychiatry. 1999;45: 32-40. (Pubitemid 29049202)
18. Saks ER. The Center Cannot Hold: My Journey Through Madness. New York, NY: Hyperion; 2007.
19. Folsom DP, Depp C, Palmer BW, et al. Physical and mental health-related quality of life among older people with schizophrenia. Schizophr Res. 2009;108:207-213.
20. Reine G, Simeoni MC, Auquier P, Loundou A, Aghababian V, Lancon C. Assessing health-related quality of life in patients suffering from schizophrenia: a comparison of instruments. Eur Psychiatry. 2005;20:510-519. (Pubitemid 41681561)
21. Shepherd S, Depp CA, Harris G, Halpain M, Palinkas LA, Jeste DV. Perspectives on schizophrenia over the lifespan: a qualitative study. Schizophr Bull. July 5, 2010; doi:10.1093/ schbul/sbq075.
22. Auslander LA, Jeste DV. Sustained remission of schizophrenia among community-dwelling older outpatients. Am J Psychiatry. 2004;161:1490-1493. (Pubitemid 38989106)
23. Ibrahim F, Cohen CI, Ramirez PM. Successful aging in older adults with schizophrenia: prevalence and associated factors. Am J Geriatr Psychiatry. 2010;18:879-886.
24. Vinogradov S, Fisher M, Holland C, Shelly W, Wolkowitz O, Mellon SH. Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia? Biol Psychiatry. 2009;66:549-553.
25. Eack SM, Hogarty GE, Cho RY, et al. Neuroprotective effects of cognitive enhancement therapy against gray matter loss in early schizophrenia: results from a 2-Year fandomized controlled trial. Arch Gen Psychiatry. 2010;67: 674-682.